Lepodisiran is an experimental medicine being tested to see if it can lower the amount of a protein called Lp(a) in the blood. High levels of Lp(a) are linked to a higher risk of heart disease. In this study, participants receive Lepodisiran as a liquid that is injected just under the skin. The goal is to find out whether the medicine can reduce the buildup of plaque in the coronary arteries of adults who already have heart disease or who are at risk for a first heart‑related event.

Cardiovascular Diseases – A group of conditions that affect the heart and blood vessels, including problems with blood flow and vessel walls. Over time, these conditions can lead to the buildup of material inside arteries, making them narrower and less flexible. As the vessels change, the heart may have to work harder to pump blood through the body. This can cause gradual changes in heart size and function. The condition often progresses silently until noticeable changes in circulation occur.
Atherosclerosis – A disease where fatty deposits build up on the inner walls of arteries, forming plaques. The plaques can grow larger, causing the arteries to become stiff and narrowed. As the narrowing worsens, blood flow to organs and tissues can be reduced. The disease typically advances over many years, with plaques gradually changing in size and composition. This process can affect any major artery in the body.
Lipoprotein(a) – A blood protein that carries cholesterol and is inherited in many people. Higher levels tend to increase over a lifetime, contributing to the formation of arterial plaques. As concentrations rise, the risk of plaque buildup in arteries may grow. The condition usually persists without obvious symptoms, but the elevated protein can influence the progression of arterial disease.